Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival

Background

Cyclin D1 is a protein essential for transition from G₁ to S phase during cell cycle progression, which has an oncogenic potential and is highly expressed in several human malignancies. However, in view of the heterogeneity of the findings in the literature, the prognostic value of cyclin D1 expression still needs to be validated in different cohorts of adult acute lymphoblastic leukemia (ALL) patients.

Methods

Bone marrow samples from 13 healthy donors and 45 adult patients with acute lymphoblastic leukemia were included. Cyclin D1 gene expression was evaluated by quantitative PCR. For statistical analysis, Mann–Whitney test, Fisher’s exact test, Chi-squared test and Cox regression were used, as appropriate. All p values were two-sided with a significance level of 5%.

Results

Cyclin D1 mRNA levels were similar between primary cells from ALL patients and healthy donors. In ALL patients, high cyclin D1 expression was associated with older age at the diagnosis, presence of BCR-ABL1, and lower white blood cell counts. Importantly, increased cyclin D1 expression was an independent factor that predicted worse overall survival in our adult ALL cohort.

Conclusion

Increased levels of cyclin D1 negatively impacted on ALL survival outcome, suggesting that this gene is involved in the malignant phenotype of ALL.

Acute lymphoblastic leukemia (ALL) is a heterogeneous group of neoplasm characterized by aberrant clonal proliferation and accumulation of B or T lymphoid immature cells in hematopoietic tissues, which impairs the normal hematopoiesis [1]. Adult ALL is associated with higher rates of death and relapse [2]. Cyclin D1 (CCND1) is an essential protein in the transition from G₁ to S phase during cell cycle progression [3], which has an oncogenic potential and is highly expressed in several human malignancies [3, 4]. In addition to its function in cell cycle control, cyclin D1 plays a role in the gene transcription regulation, cell migration, differentiation and energy balance that contributes to development and maintenance of cancer phenotype [3, 5].

The aim of the present study was to investigate the cyclin D1 (CCND1) mRNA expression and its association with clinical and laboratorial characteristics, and its impact on overall survival in a cohort of adult ALL patients.

Primary samples

Bone marrow samples were collected from 13 healthy donors from related bone marrow transplantation (median age 29 years [range 15–51]). Bone marrow or peripheral blood samples were collected from 45 patients with acute lymphoblastic leukemia (median age 35 years [range 18–79]) at the time of diagnosis (n = 40) or relapse (n = 5), followed up in the Clinical Hospital of our Institution. The median percentage of blasts in peripheral blood and bone marrow samples were 68% (range 50–88, n = 8) and 86% (range 26–100, n = 37), respectively. The study was approved by the Ethics Committee of the institution and written informed consent was obtained from all subjects who participated in this study. Patient’s characteristics are described in Table 1.

Quantitative PCR (qPCR) analysis

Total RNA was obtained from total nucleated bone marrow cells, after removal of erythrocytes by hemolysis, using TRIzol reagent (Thermo Fisher Scientific; Carlsbad, CA, USA). The cDNA was synthesized from 1 μg of RNA using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR was performed using PowerUp Sybr Green master mix (Thermo Fisher Scientific) in a 7500 Real Time PCR System (Thermo Fisher Scientific) with specific primers for cyclin D1 (CCND1; FW: CTGGGTGTCCTACAAATG; RV: AGCGGTCCAGGT AGTTCAT) and for the reference gene β-actin (ACTB; FW: AGGCCAACCGCAAGAAG; RV: ACAGCCTGGATA GCAACGTACA) using a total of 120 ng of cDNA for each replica for CCND1 and ACTB genes. ACTB was the reference gene. A negative ‘No Template Control’ was included for each primer pair. Two replicas were run on the same plate for each sample. The relative quantification value was calculated using the equation 2^-ΔΔCT.[6].

Statistical analysis

Statistical analyses were performed using GraphPad Instat 5 (GraphPad Software Inc., San Diego, CA, USA), Stata Statistic/Data Analysis 14.1 (Stata corporation, USA) and statistical package for the social sciences (SPSS) 19.0. Mann–Whitney test was used for measured factors. Fisher’s exact test or Chi-squared test was used for categorical factors. Univariate and multivariate proportional hazard regression analysis was performed for potential prognostic factors for overall survival using Cox regression. Overall survival was defined from time of sampling to date of death or last seen. Patients included in the study at the time of diagnosis (n = 40) were included in the survival analysis. All p values were two-sided with a significance level of 5%.

Cyclin D1 expression negatively impacts on ALL overall survival

Cyclin D1 mRNA levels did not differ between primary cells from healthy donors and ALL patients (median 1.38 [0.25–2.71] vs. 1.00 [range 0.06–41.09]; p = 0.49; Fig. 1a). When ALL patients were stratified according to molecular and immunophenotypic characteristics, cyclin D1 expression was significantly higher in BCR-ABL1-positive compared with BCR-ABL1-negative ALL patients (1.81 [0.16–8.83] vs. 0.72 [0.06–41.09], p < 0.05; Fig. 1b). Cyclin D1 expression did not significantly differ between B-ALL and T-ALL patients (1.20 [0.10–41.09] vs. 0.55 [0.06–1.15]; p = 0.055; Fig. 1C). High cyclin D1 expression was associated with older age at the diagnosis, presence of BCR-ABL1, and lower white blood cell (WBC) counts in ALL patients (Table 1). Importantly, increased levels of cyclin D1 and age were independent factors that predicted worse overall survival in our adult ALL cohort (Table 2).

Cyclin D1 expression in primary samples from adult acute lymphoblastic leukemia (ALL) and healthy donors. Quantitative RT-PCR analysis of cyclin D1 (CCND1) mRNA levels in samples from healthy donors and ALL patients (a) and in ALL patients stratified according to BCR-ABL1 status (b) and immunophenotype (c). The ACTB gene was used as the reference gene and a healthy donor was used as a calibrator sample. Horizontal lines indicate medians. The numbers of subjects studied are indicated in the graph. The p-values are indicated; Mann-Whitney test

Full size image

In the present study, we found no difference between the Cyclin D1 expression in primary cells from ALL patients and healthy donors. Using qPCR and Western blot assays, Wang et al. [7] observed an increased levels of cyclin D1 mRNA and protein expression in peripheral blood or bone marrow mononuclear cells of 60 ALL adult patients compared to 30 healthy donors. In contrast, Taniguchi et al. [8] did not find cyclin D1 overexpression in any of the 11 ALL patients evaluated.

We found that cyclin D1 expression independently predicted overall survival in our adult ALL cohort. Another study observed a positive correlation between cyclin D1 expression and the blast cell count in peripheral blood and bone marrow of ALL patients, but no correlation between cyclin D1 expression and WBC counts, hemoglobin level or platelet counts was found [9]. On the other hand, Elsayed et al. reported that cyclin D1 expression was not associated with response to chemotherapy and overall survival in 78 newly diagnosed adult and pediatric ALL patients [10]. High cyclin D1 mRNA levels had already been associated with poorer prognosis and relapse in childhood ALL [11, 12]. In view of the heterogeneity of the findings in the literature, the evaluation of the prognostic impact of cyclin D1 expression in ALL survival outcomes is still an open field for further investigation.

In our study, we found an association between the expression of cyclin D1 and the presence of BCR-ABL1: 8 out of 40 (20%) patients with ALL at diagnosis presented BCR-ABL1, among these, only one did not present high cyclin D1 expression. BCR-ABL1 is a potent oncogene that induces high rates of proliferation and cell cycle progression [13, 14]. Several studies have reported the relationship between BCR-ABL1 and cyclin D1 expression, mainly in chronic myeloid leukemia [14, 15]. Although BCR-ABL1 is recognized as a marker of poor prognosis in ALL [16, 17], BCR-ABL1 was not a prognostic factor in our cohort; the low number of BCR-ABL1 positive ALL cases probably interfered with the survival analysis.

In conclusion, our data indicates that cyclin D1 mRNA levels were similar between primary cells from ALL patients and healthy donors. Increased levels of cyclin D1 negatively impacted on adult ALL overall survival, suggesting the involvement of this gene in the malignant phenotype of ALL.

ACTB:

β-actin

ALL:

Acute lymphoblastic leukemia

B-ALL:

Precursor B-acute lymphoblastic leukemia

BCR-ABL1:

Breakpoint cluster region-abelson 1

CCND1:

Cyclin D1

HR:

Hazard ratio

LDH:

Lactic dehydrogenase

qPCR:

Quantitative polymerase chain reaction

RT-PCR:

Reverse transcription polimerase chain reaction

T-ALL:

Precursor T-acute lymphoblastic leukemia

WBC:

White blood cell

The authors would like to thank Andy Cumming for English review, and Amélia Góes for her valuable technical assistance.

Funding

This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado de São Paulo ; grant #2013/26213-0 and # 2013/08135-2, São Paulo Research Foundation (FAPESP).

Availability of data and materials

Please contact author for data requests.

Affiliations

1. Department of Internal Medicine, University of São Paulo at Ribeirão Preto Medical School, Av. Bandeirante 3900, Ribeirão Preto, SP, 14048-900, Brazil
   • Jaqueline Cristina Fernandes
   • , Ana Paula Nunes Rodrigues Alves
   • , Juan Luiz Coelho-Silva
   • , Renata Scopim-Ribeiro
   • , Bruna Alves Fenerich
   • , Belinda Pinto Simões
   • , Eduardo Magalhães Rego
   • , João Agostinho Machado-Neto
   •  & Fabiola Traina
2. Present Address: Department of Pharmacology, Institute of Biomedical Sciences of the University of São Paulo, São Paulo, Brazil
   • João Agostinho Machado-Neto

Contributions

JCF designed the study and experiments, performed all the experiments, manuscript preparation, completion and final approval. APNRA contributed with sample selection, inputs on overall design of study, manuscript editing and final approval. JLC-S performed statistical analysis, contributed with inputs on overall design of study, manuscript editing and final approval. RS-R and BAF contributed with inputs on overall design of study, manuscript editing and final approval. BPS and EMR participated in the interpretation of manuscript data, in manuscript editing and final approval. JAM-N participated in overall design of study and experiments, statistical analyses, manuscript preparation, editing, completion and final approval. FT was the principal investigator and participated in overall design of study and experiments, statistical analyses, manuscript preparation, editing, completion and final approval. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Fabiola Traina.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the University of São Paulo at Ribeirão Preto Medical School in accordance with the Helsinki Declaration. Written informed consent was obtained from all healthy donors and ALL patients who participated in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reprints and Permissions